Navigation Links
Xanthus Presents Novel Approach for Autoimmune Disease Reversal,with Symadex

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 3, 2007 - Xanthus Pharmaceuticals, Inc today presented data demonstrating that Symadex(TM) reversed the clinical and pathological signs of chronic disease in an animal model for multiple sclerosis. The presentation was made by Stephen J. Karlik, Ph.D., Professor of Diagnostic Radiology at the University of Western Ontario, London, Ontario, together with researchers from Xanthus in a poster session at the 59th American Academy of Neurology Meeting in Boston, MA.

Using a model of experimental autoimmune encephalomyelitis (EAE) that is designed to represent multiple sclerosis, Dr. Karlik tested Symadex for its effect on both acute and chronic disease. In the acute EAE model, animals treated with Symadex substantially recovered while in control animals the disease symptoms and damage remained unchanged. In chronic EAE disease models, clinical and pathological disease reversal and tissue recovery were observed with Symadex treatment. At the same time, Symadex did not affect circulating immune cell numbers, suggesting that it does not act as a general immunosuppressant.

"Symadex' ability to reverse chronic autoimmune disease in this animal model is notable. The study results suggest this activity may result from inhibiting macrophage function rather than inhibiting T cell function. This mechanism is novel in my experience," said Dr. Karlik.

"We now have a significant body of promising preclinical data supporting the use of Symadex in multiple autoimmune indications. We believe this represents a strong partnering opportunity for our Company, and we are preparing to initiate a human proof-of-principle trial with Symadex in autoimmune disease," stated Richard T. Dean, Ph.D., Xanthus' Chief Executive Officer.

About Symadex(TM)

Symadex (formerly C-1311) is the lead compound from a new series of agents, the imidazoacridinones, which have been shown to be po
'"/>




Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:7/31/2015)... Weiss LLP is reporting that on July 13, 2015, the ... Bard, the manufacturer of Inferior vena cava (IVC) filters ... agency found at two of Bard,s facilities. Bard was previously ... during Inspectional Observations that occurred on November 18, 2014, through ... , location and on October 6, 2014, through November 25, ...
(Date:7/31/2015)... , July 31, 2015  Boston Children,s ... benefiting from 3D printing of their anatomy before ... life-threatening cerebrovascular malformations (abnormalities in the brain,s blood ... Reporting online today in the Journal of ... of 3D printing and synthetic resins to create ...
(Date:7/31/2015)... Scientific, Inc. (Nasdaq: SMLR ), a company that ... physician groups, today reported financial results for the second ... the second quarter of 2015, Semler reported continued progress ... over quarter revenue growth of 8%, and quarter over ... of 18%," said Doug Murphy-Chutorian, M.D., chief executive officer ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 33D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
... Southern California-based philanthropy Free Wheelchair Mission has ... International,s annual giving catalog. Called "Relief in ... humanitarian outreach operations, supporting causes including hunger alleviation, ... The two international nonprofits have collaborated since 2005, ...
... , BAD HOMBURG, Germany and LACHEN, Switzerland, Oct. ... signed a License, Development and Supply Agreement regarding ... develop a HESylated recombinant protein. , Under the ... Technology to Octapharma. This technology platform is based ...
Cached Medicine Technology:OC-Based Charity Teams with International Relief Organization in Holiday Fundraising Drive 2Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein 2Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein 3
(Date:8/1/2015)... ... , ... On March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for ... by stepping off Springer Mountain and heading north. Since that day, Phil has hiked over ... was greeted by friends and family. He visited CCAR and left an inspirational message ...
(Date:7/31/2015)... ... August 01, 2015 , ... Super Bowl 50 will emanate from Levi’s Stadium in ... each year is the Super Bowl. In the two weeks that separate the conference championships ... venue. The 2016 Super Bowl game will mark the 50th time it has been held ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight On ... on October 3, 2015. The Ride to Fight On is a cycling fundraiser that ... Healthcare, The West Clinic and The University of Tennessee Health Science Center. A health ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Coco Libre announced ... judges, media, and VIPs at the 2015 Vans US Open of Surfing, July 25 ... that can claim “no added sugar” on the market, is a natural choice given ...
(Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique ... wedding cakes with custom designs, making life just a little bit sweeter ... wedding cakes for each customer who orders one. , The bakery provides a full ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... created an uptick in his business as more people find themselves either ... back. , ... Concord, CA (PRWEB) April 3, 2009 -- As economies ... play out for the young but booming medical tourism industry . ...
... As news emerged that Gov. Kathleen Sebelius, nomination ... postponed until the end of April, American Life ... Pat Roberts to reject the nomination.(Logo: ... Courtesy" -- the longstanding Senate tradition only confirming ...
... completion may boost patient compliance, outcomes, researchers say , , ... antibiotic called moxifloxacin in combination with other drugs could ... takes to cure patients with drug-treatable tuberculosis, according to ... result in patients failing to complete their drug therapy, ...
... Event highlights accomplishments of three highly recruited adapted sports ... rehabilitation and resource center Courage Center has had a ... in adapted sports such as wheelchair basketball and rugby. ... high school seniors will sign college letters of intent ...
... the release of the first long-range plan for tackling ... Americans each year. , Opportunities and Challenges in Digestive ... Diseases describes the impact of diseases ranging from foodborne ... priorities for research over the next 10 years. The ...
... Healthcare Holdings, Inc. announced today that it has agreed ... County Physicians Investment Network, LLC, which is owned primarily ... shareholders, and certain related parties of OC-PIN. The ... in May, 2007 against two of its former directors ...
Cached Medicine News:Health News:Economic Turmoil Creates Boom for Medical Tourism 2Health News:Economic Turmoil Creates Boom for Medical Tourism 3Health News:Economic Turmoil Creates Boom for Medical Tourism 4Health News:A.L.L. Calls on KS Senators to Stop Sebelius as Confirmation Postponed 2Health News:New Antibiotic Could Shorten TB Treatment 2Health News:Courage Center Hosts College Scholarship Signing Ceremony Thursday, April 9, 2009 2Health News:NIH releases the first research plan to reduce the burden of digestive diseases 2Health News:NIH releases the first research plan to reduce the burden of digestive diseases 3Health News:IHHI Settles Litigation With OC-PIN 2
For the qualitative determination of magnesium in serum....
Intended for the quantitative determination of magnesium in serum or plasma. Reaction: Endpoint. Wavelength: 520 nm. Linearity: 6.0 mg/dL (2.5 mmol/L)....
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution....
For the quantitative determination of total glucose in serum....
Medicine Products: